Role of the ATP7A Transporter in Ovarian Cancer

Ovarian Cancer Clinical Trial

— ATHOC  

Official title:

ATP7A Transporter as Biomarker for Predicting Chemoresistance of Serous Ovarian Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05490407
• Other study ID #: UMCL
• Status: Completed
• Phase: N/A
• Start date: March 17, 2021
• Est. completion date: January 1, 2024

Study information

• Verified date: January 2024
• Source: University Medical Centre Ljubljana
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ovarian cancer has the highest mortality rate among all gynecologic cancers, with most patients presenting with advanced stage tumors. About a third of patients do not respond to primary platinum-based chemotherapy treatment, and over time up to 80 % of others develop chemoresistance, rendering recurrent disease incurable. Despite all the studies published in the literature, it has not been proven that the number of cells with expressed ATP7A in certain tumors increases independently of the therapy. In addition, no study has been conducted on a sample of patients with confirmed serous histology of ovarian cancer only. The aim of the study is to demonstrate increased expression of the ATP7A transporter in cells resistant to carboplatin.

Description:

RATIONALE:

Recent studies suggest that the copper efflux transporters ATP7A plays an important role in platinum resistance. Despite all the studies published in the literature, it has not been proven that the number of cells with expressed ATP7A in certain tumors increases independently of the therapy. In addition, no study has been conducted on a sample of patients with confirmed serous histology of ovarian cancer only. The literature concludes that new methods are required to detect resistant tumor cells at an early chemotherapy stage and suitably adapt treatment. There is still much uncertainty regarding how the fate of platinum compounds in a cell follows the regulatory copper pathways, especially during transport from the cell. The question is also to what extent these processes are cell-specific, especially because experiments to date regarding the role of ATP7A in resistance to platinum compounds have been conducted on nonserous cell lines (especially of the endometrioid histological type).

AIM OF THE STUDY:

Study will evaluate the ATP7A transporter as an important mediator of chemoresistance to platinum compounds to obtain an additional criterion for the optimal treatment strategy for serous ovarian cancer patients. The focus will primarily be on intrinsic chemoresistance, which determines the initial response to chemotherapy. Research to date has failed to evaluate the influence of ATP7A transporter expression solely on serous ovarian cancer.

The study will demonstrate increased expression of the ATP7A transporter in cells resistant to carboplatin. Because the measurement of ATP7A in bodily fluids is unreliable, the plan is to measure ceruloplasmin in the patients' ascites. Ceruloplasmin is the main copper-transporting protein in the blood. It is synthesized in the cell and, according to findings in the literature, it is ATP7A that is responsible for delivering copper to ceruloplasmin. When copper binds to ceruloplasmin, there is no other way for it to cross the plasma membrane than via the ATP7A transporter. By measuring the ceruloplasmin level in the ascites, ATP7A activity or its localization on the plasma membrane could indirectly be measured as well. To confirm the suitable measurement of ceruloplasmin in the ascites, its values in the patients' blood plasma and tissue will be measured.

METHODS:prospective clinical trial It will include 30 high-grade serous ovarian cancer patients (FIGO stages III and IV) with ascites. The patients will be presented to the gynecological-oncological consultation team at the Ljubljana Division of Gynecology and Obstetrics. Patients for whom neoadjuvant chemotherapy is recommended will be included in the trial.

STATISTICAL ANALYSES: The normality of numerical variables' distribution will be tested with the Shapiro-Wilk test. Relevant parametric tests (Student's t-test) or nonparametric tests (the two-tailed Mann-Whitney U-test) will be used to compare groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: January 1, 2024
• Est. primary completion date: May 1, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• high-grade serous ovarian cancer patients (FIGO stages III and IV) with ascites, for whom neoadjuvant chemotherapy is recommended

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Chemotherapy Effect
• Gynecologic Cancer
• High Grade Serous Carcinoma
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• Carboplatin
Patients will receive neoadjuvant chemotherapy according to ESGO guidelines

Locations

Country	Name	City	State
Slovenia	Department of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Center	Ljubljana
Slovenia	Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana.	Ljubljana

Sponsors (2)

Lead Sponsor	Collaborator
University Medical Centre Ljubljana	University of Ljubljana, Faculty of Medicine, Institute of Pharmacology and Experimental Toxicology

Country where clinical trial is conducted

Slovenia, 

References & Publications (5)

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062. — View Citation

Lukanovic D, Herzog M, Kobal B, Cerne K. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Biomed Pharmacother. 2020 Sep;129:110401. doi: 10.1016/j.biopha.2020.110401. Epub 2020 Jun 20. — View Citation

Lukanovic D, Kobal B, Cerne K. Ovarian Cancer: Treatment and Resistance to Pharmacotherapy. Reproductive Medicine. 2022; 3(2):127-140. https://doi.org/10.3390/reprodmed3020011

Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004 Jul 15;10(14):4661-9. doi: 10.1158/1078-0432.CCR-04-0137. — View Citation

Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5853-9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	concentration of ceruloplasmin	To measure concentration of ceruloplasmin in blood and ascites	before the start of neoadjuvant chemotherapy
Primary	expression of ATP7A	To measure expresion of ATP7A	before the start of neoadjuvant chemotherapy
Secondary	concentration of ceruloplasmin after chemotherapy	To measure concentration of ceruloplasmin after three to six chemotherapy cycles	after neoadjuvant chemotherapy - within 6 months
Secondary	expresion of ATP7A after chemotherapy	To measure expresion of ATP7A after three-six cycles of chemotherapy	after neoadjuvant chemotherapy - within 6 months